- Email us: sales@msbdocs.com
The European Medicines Agency (EMA) is a decentralized EU agency responsible for the evaluation, supervision, and safety monitoring of medicines. In EMA-regulated workflows, electronic signatures (eIDAS-compliant) ensure that all regulatory documents from clinical trial approvals to post-market monitoring records are legally valid, secure, auditable, and tamper-evident.
Compliance in these environments is further aligned with EU GMP Annex 11 requirements for computerized systems, ensuring validated systems, audit trails, access controls, and data integrity across the full lifecycle of medicines.
EMA regulates medicines across the EU to make sure they are safe, effective, and of high quality for patients. Its oversight spans clinical trials, regulatory approvals, manufacturing, and post-market monitoring, ensuring public health is protected at every stage.
EMA requires organizations to maintain accurate, complete, and auditable records, including clinical trial data, approvals, batch release documents, and quality management records. Compliance with these standards is critical to meet EU regulatory expectations.
EMA-regulated workflows accept eIDAS-compliant electronic signatures, ensuring that approvals and submissions are legally valid, traceable, secure, and tamper-evident. This enables digital documentation without compromising regulatory compliance.
Electronic signatures combined with secure recordkeeping help organizations maintain data integrity, accountability, and inspection readiness, making audits and regulatory inspections simpler and more reliable.
By adopting EMA-aligned digital tools, organizations can accelerate approvals, reduce manual errors, and execute workflows efficiently across the full lifecycle of medicines from research and clinical trials to post-market reporting.
EMA’s centralized framework ensures companies can operate across EU Member States while meeting uniform regulatory standards, reducing complexity and ensuring consistent compliance across all markets.
Avoid Penalties, Delays, & Audit Failures with
secure digital records.
To streamline regulatory processes and ensure data integrity, EMA supports the use of electronic signatures in compliance with the EU eIDAS Regulation (Regulation (EU) No 910/2014). Electronic signatures under eIDAS provide:
Under eIDAS, electronic signatures are categorized into three levels:
Each signature is uniquely linked to the signer
Records cannot be altered without detection
EMA-regulated processes may involve electronic signatures for a range of regulatory documents, including certificates for medicines, submission approvals, and inspection-ready records, ensuring that electronic documentation is secure, auditable, and legally recognized.
MSB Docs is designed to support EMA-regulated workflows, enabling pharmaceutical and life sciences organizations to manage secure, compliant, and audit-ready documentation. The platform:
Supports legally valid electronic signatures compliant with the eIDAS Regulation, including Qualified Electronic Signatures (QES) where required.
Maintains secure, tamper-evident audit trails in alignment with EU GMP Annex 11 requirements for computerized systems.
Ensures data integrity, traceability, validated system controls, and inspection readiness in accordance with EU GMP guidelines.
Helps organizations execute EMA-regulated workflows efficiently, from clinical trial documentation to regulatory submissions — with support for validation requirements under both EU GMP Annex 11 and 21 CFR Part 11 for global EU–US operations.
With MSB Docs, organizations can confidently comply with EMA requirements while digitizing their documentation and approval processes.